Proficio Capital Partners LLC Increases Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Proficio Capital Partners LLC raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 25,929.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 193,660 shares of the biopharmaceutical company’s stock after purchasing an additional 192,916 shares during the quarter. Proficio Capital Partners LLC owned 0.15% of Alnylam Pharmaceuticals worth $45,570,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ALNY. Huntington National Bank raised its position in Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the period. Hollencrest Capital Management purchased a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $29,000. R Squared Ltd purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $33,000. Washington Trust Advisors Inc. purchased a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $42,000. Finally, True Wealth Design LLC raised its position in Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 153 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on ALNY. Wolfe Research downgraded shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Scotiabank dropped their price target on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a research note on Friday, February 14th. Needham & Company LLC restated a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday. Royal Bank of Canada restated an “outperform” rating and issued a $310.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday. Finally, Canaccord Genuity Group boosted their price target on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $304.26.

Insider Activity

In other news, CMO Pushkal Garg sold 1,752 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $251.00, for a total value of $439,752.00. Following the completion of the sale, the chief marketing officer now directly owns 15,705 shares of the company’s stock, valued at approximately $3,941,955. This represents a 10.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the sale, the executive vice president now directly owns 12,881 shares of the company’s stock, valued at $3,240,344.36. The trade was a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 72,986 shares of company stock valued at $20,397,849. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $246.75 on Friday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The stock has a market cap of $31.94 billion, a PE ratio of -113.71 and a beta of 0.35. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The firm has a fifty day moving average price of $254.30 and a 200 day moving average price of $262.42.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.